Description: Cost sharing reduction (CSR) payments are offered to low-income individual insurance buyers under the ACA. After October 2017, the difference in costs between the standard silver plan and CSR variants were defunded. To cover the costs of defunding, insurers have increased rates either through "broad loading" or "silver loading." States are approaching this adjustment differently, which is leading to some interesting differences between states. This article will review these differences.

Description: Traditional Medicare [TM] has many coverage gaps and no out-of-pocket maximum. Most members must purchase a Medicare Supplement Plan and a Part D plan for pharmacy coverage. Over 50% of members have opted for a Medicare Advantage [MA] plan that replaces TM and the need to purchase a Supplement and (in most cases) a Part D plan. All this for less cost to the member, but at a greater overall cost to the federal government even though MA plans provide TM benefits for less than it costs the government. The attendee will learn why this occurs. However, given these facts, the focus of the session will be on the future of Medicare: namely, should the parameters regarding MA bids and payments be limited to what is paid for TM, or can we take the best administrative techniques of MA and TM to provide more robust benefits for all Medicare members at a cost no greater than the government is currently paying? Or is there an even better idea?

Description: Panel discussion of managers of actuaries discussing do's and don'ts of managing actuaries in a virtual world. When employees no longer come into the office five days per week, eight hours each day, how do you maintain productivity, team building, morale? How do you facilitate team work and ensure camaraderie is improved? The great reset, not the great resignation! As employees figure out if they want to be 100% remote, or 100% in the office, or somewhere in between, and employers determine their stance on in-office for virtual, the actuarial workforce is resetting itself with employees finding their lifestyle match with employers. Zoom, Teams, WebEx - 'you're on mute' might be the most used business phrase in the past 4 years! Managers can glean helpful insights that will make them more effective managing their actuarial teams.

Description: There are a variety of regulatory changes that are being contemplated by the National Association of Insurance Commissioners (NAIC) that have the potential to materially impact actuarial, statutory reporting and disclosure requirements relating to reinsurance. This session will provide an introduction to these changes, explaining both the motivation as well as the potential impact these proposed changes may have on US ceding companies. The focus of the presentation will be primarily on changes affecting Asset Adequacy Testing and statutory risk transfer for combination Coinsurance / Yearly Renewable Term agreements. An update will be provided regarding industry responses to proposed changes and the potential timing for implementation of these new requirements.

Description: This session will focus on the topic of Bermuda Reinsurance: Operational Readiness for Changes. The presenters will examine the current state of the reinsurance industry in Bermuda and explore the operational strategies that companies must consider to stay ahead in a rapidly evolving market. The discussion will cover regulatory updates, and market shifts that are influencing the way reinsurance businesses operate. The presenters will also discuss operational capabilities and organizational structure to think about when designing a new entity.

Description: Prescription drug markets are undergoing rapid change - significant policy changes implemented through the Inflation Reduction Act, Congressional interest in long-awaited 340b reform, and a growing direct-to-consumer market have already changed the landscape significantly. The ongoing effects of these changes will continue to evolve for many years. Hear from leading prescription drug actuaries and pharmacy policy experts on what these changes mean for prescription drug markets and US healthcare more broadly.